Several nanoformulated anti-cancer substances are currently commercialized or under
development. Pre-clinical and clinical results have revealed better properties, that is, larger …

Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (> 65 years of age) and
this population is expected to increase in the following years. A simplified geriatric …

Liposomes are a class of well-established drug carriers that have found numerous
therapeutic applications. The success of liposomes, together with recent advancements in …

Doxorubicin (DOX) is a widely used and effective antineoplastic drug; however, its clinical
application is limited by cardiotoxicity. A safe and effective strategy to prevent from …

Background Anthracycline chemotherapeutics, such as doxorubicin, are used widely in the
treatment of numerous malignancies. The primary dose-limiting adverse effect of …

(1) Background: Doxorubicin (DOX) is extensively used for cancer treatments; however, its
clinical application is limited because of its cardiotoxic adverse effects. A combination of …

Doxorubicin plays an integral role in the treatment of patients with diffuse large B-cell
lymphoma (DLBCL) but can be associated with significant toxicity. Treatment guidelines of …

Purpose The treatment of patients with diffuse large B-cell lymphoma (DLBCL) with cardiac
comorbidity is problematic, because this group may not be able to receive anthracycline …

Abstract The European Society for Medical Oncology (ESMO) consensus conference on
mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June …

Rationale: Clinical application of doxorubicin (DOX) is limited by its toxic cardiovascular side
effects. Our previous study found that toll-like receptor (TLR) 5 deficiency attenuated cardiac …